Director/Senior Director, US Marketing job in San Diego
Share
Tweet
LinkedIn
San Diego, California - CA Kura Oncology
| Job Ref: | 5751870004 |
| Employer: | Kura Oncology |
| Category: | General Marketing |
| Salary and Benefits: | USD 224,000.00 - 260,000.00 per year |
Location | |
| State: | California - CA |
| City: | San Diego |
| Map: | United States, California , San Diego (Show on map) |
Description | |
|
Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions. ESSENTIAL JOB FUNCTIONS: Join us as we embark on an exciting journey in transforming the treatment landscape of acute myeloid leukemia (AML). We are searching for a Director / Senior Director, KOMZIFTI (ziftomenib) Marketing, to report directly to the Executive Director of Marketing. The successful candidate will be responsible for the strategic planning and execution of HCP and Consumer marketing and will aid value and access pull through to support the recent approval of KOMZIFTI in relapsed / refractory (R/R) NPM1-m AML. This role requires strong leadership to strategically drive and cross-functionally integrate across internal and external teams. The ideal candidate will bring deep experience in oncology / hematology marketing, insight-driven planning, and operational excellence. This is a high-visibility role with regular engagement across senior leadership, key decision-makers, and sales, offering the opportunity to make a meaningful impact on the success of KOMZIFTI and the lives of patients with R/R NPM1-m AML. Responsibilities Strategic Planning & Brand Management
Brand Management
Marketing Execution
Sales Enablement & Cross-Functional Collaboration
Performance Management
Compliance & Governance
The preceding job description has been designed to indicate the general nature and level of work performed by employees within this classification. It is not designed to contain or be interpreted as a comprehensive inventory of all duties, responsibilities and qualifications required of employees assigned to the job. JOB SPECIFICATIONS:
QUALIFICATIONS:
Preferred Qualifications
The base range for this role at the Director level is $224,000 - $260,000 and Senior Director level is $268,000 - $295,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1 Kura's Values that are used for candidate selection and performance assessments:
The Kura Package
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration ("FDA") for the treatment of relapsed/refractory ("R/R") NPM1-mutant acute myeloid leukemia ("AML"). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at www.kuraoncology.com and follow us on X and LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. If you are a California resident, please see the attached Privacy Notice CA Privacy Notice | |
ref: (5751870004) 8 hours ago
Back to search results
